A majority of patients with barrett’s oesophagus are unlikely to benefit from endoscopic cancer surveillance

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 6, 2001, Pages 639-645

  Gudlaugsdottir, Sunna ^a   Blankenstein, Mark Van ^a   Dees, Jan ^a   H Paul Wilson, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barrett s oesophagus; Endoscopic surveillance; Oesophageal adenocarcinoma

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; DYSPLASIA; ENDOSCOPY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 0034970813     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200106000-00005     Document Type: Article

References (57)

1. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975; 70: 826-835.
2. Cameron AJ, Lomboy CT. Barrett’s esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-1245.
3. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-922.
4. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali MH, Sassoon L. A single centre’s 20 years’ experience of columnar-lined (Barrett’s) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999; 11: 1355-1358.
5. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett’s esophagus. Am J Clin Pathol 1987; 87: 301-312.
6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289.
7. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG. et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology 1984; 87: 927-933.
8. Sprung DJ, Ellis FH, Gibb SP. Incidence of adenocarcinoma in Barrett’s esophagus [Abstract]. Am J Gastroenterol 1984; 79: 817.
9. Sampliner RE, Sharma P, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus-1/230 patient years of follow-up [Abstract]. Am J Gastroenterol 1999; 94: 2599.
10. Van der Veen AH, Dees J, Blankensteijn JD, van Blankenstein M. Adenocarcinoma in Barrett’s oesophagus: An overrated risk. Gut 1989; 30: 14-18.
11. Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett’s esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
12. Polepalle SC, McCallum RW. Barrett’s esophagus. Current assessment and future perspectives. Gastroenterol Clin North Am 1990; 19: 733-744.
13. Ollyo JB, Lang F, Fontolliet Ch, Krayenbuhl F, Monnier Ph, Savary M. et al. Barrett’s esophagus: surveillance follow-up by esophagoscopy, colonoscopy or panendoscopy? [Abstract]. Gastroenterology 1990; 98: A100.
14. Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz HT, Heatley GJ. et al. Barrett’s esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151: 2212-2216.
15. Watson RGP, Porter KG, Sloan JM. Incidence of adenocarcinoma in Barrett’s oesophagus and an evaluation of endoscopic surveillance. Eur J Gastroenterol Hepatol 1991; 3: 159-162.
16. Sampliner R, Mackel C, Fennerty MB, Garewal HS. Prospective incidence of cancer in Barrett’s esophagus [Abstract]. Gastroenterology 1991; 100: A153.
17. Karras DJ, Michalos A. Importance of endoscopic surveillance in Barrett’s esophagus [Abstract]. Gastroenterology 1991; 100: A95.
18. Bonelli L. Barrett’s esophagus: Results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Endoscopy 1993; 25: 652-654.
19. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut 1991; 32: 1441-1446.
20. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett’s oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-1158.
21. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut 1996; 39: 5-8.
22. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus: A prospective study of 170 patients followed 4. 8 years. Am J Gastroenterol 1997; 92: 212-215.
23. O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: Report on the Cleveland Clinic Barrett’s Esophagus Registry. Am J Gastroenterol 1999; 94: 2037-2042.
24. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94: 3413-3419.
25. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett’s esophagus. Am J Gastroenterol 1998; 93: 536-541.
26. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett’s esophagus. Dig Dis Sci 1989; 34: 1336-1339.
27. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus. Br J Surg 1988; 75: 760-763.
28. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett’s esophagus. Am J Gastroenterol 1988; 83: 291-294.
29. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 1985; 313: 857-859.
30. Böhmer CJ, Hop WCJ, Meuwissen SGM, van Blankenstein M. Carcinoma of Barrett’s esophagus, do smoking and alcohol really matter? [Abstract]. Gastroenterology 2000; 118: A459.
31. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL. et al. Cost effectiveness of detecting Barrett’s cancer. Gut 1996; 39: 574-579.
32. van Sandick JW, van Lanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obetop H. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 1998; 43: 216-222.
33. Macdonald CE, Wicks AC, Playford RJ. Final results from 10-year cohort of patients undergoing surveillance for Barrett’s oesophagus: observational study. BMJ 2000; 321: 1252-1255.
34. Wilson JM, Jungner YG. Principles and practice of screening for disease. Geneva: World Health Organization; 1968. (Public health papers no. 34).
35. Provenzale D, Kemp AJ, Arora S, Wong JB. A guide for surveillance of patients with Barrett’s esophagus. Am J Gastroenterol 1994; 89: 670-680.
36. Pereira AD, Suspiro A, Chaves P, Saraiva A, Glória L, Mendes de Almeida JC. et al. Short segments of Barrett’s epithelium and intestinal metaplasia in normal appearing oesophagogastric junctions: The same or two different entities? Gut 1998; 42: 659-662.
37. Clark GW, Smyrk TC, Hoeft SF, Burdiles P, Dreuw B, Crookes PF. Is the length of Barrett’s mucosa related to the prevalence of complications and adenocarcinoma in Barrett’s esophagus? [Abstract]. Gastroenterology 1993; 104: A393.
38. Menke-Pluymers MBE, Hop WCJ, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-1158.
39. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett’s esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-388.
40. Mackenbach JP, Kunst AE, Lautenbach H, Oei YB, Bijlsma F. Competing causes of death: A death certificate study. J Clin Epidemiol 1997; 50: 1069-1077.
41. Mendes de Almeida JC, Chaves P, Pereira AD, Altorki NK. Is Barrett’s esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg 1997; 226: 725-735.
42. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344: 1533-1536.
43. Nandurkar S, Talley NJ. Barrett’s esophagus: The long and the short of it. Am J Gastroenterol 1999; 94: 30-40.
44. Gopal DV, Faigel DO, Magaret N, Fennerty MB, Sampliner RE, Garewal HS. et al. Risk factors for dysplasia in patients with Barrett’s esophagus (BE): Results from a multicenter consortium [Abstract]. Gastroenterology 1999; 116: A175.
45. Cameron AJ, Carpenter HA. Barrett’s esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol 1997; 92: 586-591.
46. Attwood SEA, DeMeester TR, Bremner CG, Barlow AP, Hinder RA. Alkaline gastroesophageal reflux: Implications in the development of complications in Barrett’s columnar-lined lower esophagus. Surgery 1989; 106: 764-770.
47. Gray MR, Donnelly RJ, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett’s columnar lined oesophagus. Gut 1993; 34: 727-731.
48. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS. et al. Adenocarcinoma of the esophagus: Role of obesity and diet. J Natl Cancer Inst 1995; 87: 104-109.
49. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL. et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150-155.
50. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA 1993; 270: 1320.
51. Van Laethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: Immediate and mid-term results. Gut 1998; 43: 747-751.
52. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ. et al. Photodynamic therapy for dysplastic Barrett’s oesophagus: A prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47: 612-617.
53. van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RWF, Tilanus HW. Endoscopic ablation therapy for Barrett’s esophagus with high-grade dysplasia: A review. Am J Gastroenterol 1999; 94: 1153-1160.
54. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett’s esophagus with high-grade dysplasia: An indication for esophagectomy? Ann Thorac Surg 1992; 54: 199-204.
55. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333-338.
56. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-2053.
57. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS. et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132: 612-620.